Table 2.
Incidence of nonhematologic adverse events reported for dasatinib treatment.
| Adverse events | Patients (%) | |||
|---|---|---|---|---|
| First-line | Second-line | |||
| Dasatinib 100mg daily | Dasatinib 100mg daily | |||
| Any Grade | Grade 3/4 | Any Grade | Grade 3/4 | |
| Hematologic toxicity | ||||
| Neutropenia | 7-64 | 6-29 | 12-64 | 12-63 |
| Leukopenia | 4 | 1 | 8-61 | 1-24 |
| Anemia | 13-90 | 3-13 | 23-91 | 6-20 |
| Thrombocytopenia | 18-70 | 9-22 | 23-65 | 11-57 |
| Non-hematologic toxicity | ||||
| Gastrointestinal toxicity | ||||
| Diarrhea | 17-59 | 0-5 | 9-37 | 0-3 |
| Nausea | 8-52 | 0-3 | 18-27 | 0-1 |
| Vomiting | 5-30 | 0-2 | 10 8 2 7 | 0-1 |
| Abdominal pain | 17 | 3 | 15 3 12 | 0-1 |
| Musculoskeletal toxicity | ||||
| Muscle spasms | 5-8 | <1 | 1 | 0 |
| Myalgia | 6 | <1 | 13-37.6 | 0-1.8 |
| Musculoskeletal pain | 11-69 | <8 | 19-21 | 1-2 |
| Cutaneous disorder | ||||
| Rash | 11-27 | 0 | 8-32.8 | 0-3 |
| Metabolic disorders | ||||
| Hyperlipidemia | NR | NR | NR | NR |
| Hyperglycemia | 13 | 1 | NR | NR |
| Hepatotoxicity | 26 | 1 | NR | NR |
| Nephrotoxicity | 17 | 2 | NR | NR |
| General Disorders | ||||
| Headache | 12-48 | 0-5 | 15-33 | 1-2 |
| Fatigue | 8-76 | 1-13 | 2-37 | 0-4 |
| Pulmonary disorders | ||||
| Pleural effusions | 10-35 | 0-9 | 9-26 | 2-8 |
| Pulmonary arterial hypertension | 2.6-5 | 0-1 | 2.4 | 1.1 |
| Cardiovascular Toxicity | ||||
| QTc prolongation | 1.6-73 | NR | NR | NR |
| Arterial vascular events | 5 | 0-1 | 4 | 0-1 |
NR, not reported.